Solid-phase reverse transfection on cell microarrays is a high-throughput method for the parallel transfection of mammalian cells. However, the cells transfected in this way have been restricted so far to microscopy-based analyses. Analysis methods such as reverse transcriptase-polymerase chain reaction (RT-PCR) and access to higher cell numbers for statistical reasons in microscopy-based assays are not possible with solid-phase reverse transfection on cell microarrays. We have developed a quick and reliable protocol for automated solid-phase reverse transfection of human cells with siRNAs in multiwell plates complementing solid-phase reverse transfection on cell microarrays. The method retains all advantages of solid-phase reverse transfection such as long-term storage capacity after fabrication, reduced cytotoxicity, and reduced cost per screen compared with liquid-phase transfection in multiwell plates. The protocol has been tested for the RNAi-mediated knockdown of several genes in different cell lines including U20S, RPE1, A549, and HeLa cells. We show that even 3 months after production of the "ready to transfect" multiwell plates, there is no reduction in their transfection efficiency as assessed by RT-PCR and nuclear phenotyping by fluorescence microscopy. We conclude that solidphase reverse transfection in multiwell plates is a cost-efficient and flexible tool for multiplexing cellular assays. (Journal of Biomolecular Screening. 2008:575-580) 
INTRODUCTION
H IGH-THROUGHPUT TRANSFECTION and highly correlative methods are the basis for cell-based systems biology. Solid-phase reverse transfection on cell microarrays 1 is a highthroughput method for the parallel transfection of mammalian cells. GFP-tagged cDNAs or small interfering siRNAs [2] [3] [4] [5] [6] are printed together with a gelatin solution at defined locations on glass slides. A transfection reagent can be printed together with the nucleic acid or can be added to the printed microarray prior to cell seeding. The widely used variant of printing the nucleic acid precomplexed with the transfection reagent has the advantage that after drying, the printed microarrays are "ready to transfect." Tissue culture cells are plated on the dried slides resulting in clusters of live cells with a specific gene perturbation in a lawn of nontransfected cells. The method is called "reverse transfection," because in contrast to conventional transfection the order of addition of siRNAs or expression plasmids and cells is reversed. The miniaturized format of the microarray allows high-speed data acquisition, for example, time-lapse data acquisition of many samples in parallel. 7 The dried and ready-to-transfect replicas can be stored for more than 15 months. 8 The long storage capacity of the printed replicas makes this technique the method of choice for highthroughput transfection, allowing a better correlation between different assays performed on replicas of the same production day and reduces the cost per assay.
Disadvantages of the microarray-based solid-phase reverse transfection technique are a reduced statistical relevance of the single experiment due to the small number of cells per spot and that no subsequent analysis such as, for example, reverse transcriptase-polymerase chain reaction (RT-PCR) can be performed. In addition, because no walls separate the individual experiments there exists possibility for cross-contamination of the individual spots and thus distortion of the results. 
MATERIALS AND METHODS

Materials
Reagent setup
Growth medium: DMEM supplemented with 10% (vol/vol) heat-inactivated fetal calf serum, 2 mM glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin. 
Equipment
Methods
Transfection protocol for liquid-phase transfection in 96-well plates
One day before transfection, plate 5 × 10 3 HeLa cells in 100 μl of growth medium without antibiotics in each well.
Preparation of transfection mix: Combine and mix solution (a) with (b) and incubate for 20 min.
Replace the medium of the cells with 80 ml of serum-free DMEM.
Add 20 μl of the transfection mix to each well. Four hours after transfection add 50 ml of DMEM including 3× concentrated sera, glutamine, and antibiotics. 1 . Prepare an siRNA stock solution by dissolving lyophilized siRNAs with milliQ water to a final concentration of 30 μM. Comment: The preparation can be done manually or by an automated liquid handler (e.g., "MICROLAB STAR" by Hamilton). Comment: From the source siRNA transfection solution, 16 independent sets of 96-well plates can be prepared in parallel.
Preparation of the source siRNA transfection solution for solid-phase transfection
Automated preparation of 96-well plates "ready to transfect"
Preparation of 384-well plates "ready to transfect"
11. Use 0.25 μl of the source siRNA transfection solution and add 10 μl of MilliQ water per well of a 384-well plate (Greiner). 12. Dry the 384-well plates for 2.5 h at medium drying force in the Speed Vac.
Comments: For 384-well plates "ready to transfect," no automated protocol is available yet. The source siRNA transfection solution allows the preparation of up to 64 ready-totransfect 384-well plates.
Preparation of 2-well LabTek chambered coverglass "ready to transfect"
13. For 2-well, LabTek chambered coverglass, we carefully mix 1000 μl of MilliQ water and 13 μl of the source siRNA transfection solution in an Eppendorf tube and transfer the solution to 1 well of a 2-well LabTek chambered coverglass. 14. Dry the 2-well, LabTek chambered coverglass for 2.5 h at medium drying force in the Speed Vac.
Comment: One well of a 2-well LabTek chamber can be prepared from the source transfection solution. They are used when high cell numbers are required (e.g., search for rare events).
Application of cells
Use actively growing cells of the different cell types and apply them on the substrates in the above-described cell growth medium (DMEM). 
Long-term storage conditions
Store the dried and immediately usable multiwell plates in a gel drying box (The Stewart Company) with drying pearls, orange-heavy metal free (Fluka, catalog number 94098).
RT-PCR
Forty-eight hours following transfection in 96-well plates, total RNA was extracted from cells (Invisorb Spin Cell RNA mini kit, Invitek), followed by cDNA synthesis using random hexamers and Taqman RT reagents (Applied Biosystems). Real-time quantitative RT-PCR was performed using target-specific oligonucleotide primers (see below) and SYBRgreen PCR mastermix (Applied Biosystems) on an ABI 7500 system (Applied Biosystems). Knockdown efficiency was determined by calculating remaining target mRNA and comparing siRNA-treated samples with nonsilencing unspecific control siRNA samples (both Ambion Europe, Ltd.). All measurements are normalized to the endogenous control GAPDH. 
Target-specific oligonucleotide primers
Incenp_F1 CACAACTACGGGATGGATCTGA Incenp_R1 GATATCCTCCAAGTCCAGTGGG Eg5_F1 CCAGCAAGCTGCTTAACACAGT Eg5_R1 CTTCTAGCATGGCCTTTTGCTT BetaCOP_F1 TCTCAGTGACAACAACGAAGCA BetaCOP_R1 TGCTCCTCGGTAAATCTTGACA GAPDH_F1 CACCAGGGCTGCTTTTAACTCT GAPDH_R1
Image acquisition
Images are acquired with a "Scan^R" (Olympus Biosystems) automated epifluorescence microscope (I×81) equipped with a stabilized light source (MT20) and firewire cameras (DB-H1 1300 × 1024).
Autofocus is image based to focus on the maximum number of healthy cells (scoring size, intensity, and contrast).
• Depending on magnification required, choose objective. We used for these experiments a 10×/0.4 air objective (Olympus, catalog number UPSLAPO 10×). • Choose filter sets: DAPI, HQ-Filter (bandpass) and for GFP (bandpass) (Chroma, Europe). • Choose exposure time according to dye. We used 40 ms for GFP-tagged histone 2B and 7 ms for DAPI stained nuclei. • Assign the first well of the multiwell plate. This we do in bright-field illumination. • Assign the number of images acquired in each well of the multiwell plate. • Start automated data acquisition.
RESULTS AND DISCUSSION
We have developed a quick and automated protocol for solid-phase reverse transfection with siRNAs in multiwell plates (384-well plates, 96-well plates, and 2-well LabTeks chambers) allowing multiplexing of diverse biological assays requiring high cell numbers or follow-up manipulations of the cells such as real-time RT-PCR.
In Figure 1 , an overview of the production of 96-well substrates and the multiplexing capacity of solid-phase reverse transfection in multiwell plates is shown. siRNAs and transfection solutions are automatically mixed on a liquid handler and transferred into 96-well plates. Thereafter, the multiwell plates are dried in a Speed Vac. Presently, the capacity of the Speed Vac limits the number of plates that can be produced (16 plates per load). However, by using a high loading capacity Speed Vac the number of replicates that could be produced could be easily upscaled. We are at the moment able to produce 48 replicas per day (assuming 3 loads of the Speed Vac per day). In combination with the long-term storage capacity and assuming that 3 replicates per assay are needed we can produce substrates for 16 different assays per day. To speed up the drying process it might be possible to raise the temperature in the Speed Vac or to reduce the volume needed per well for producing more plates per day. However, it will be necessary to test the efficiency of transfection in plates produced in such a way.
To optimize conditions and to demonstrate the performance of the technique we produced plates with siRNAs targeting 4 genes (EG5 [microtubule motor protein], PLK1 [polo-like kinase 1] and Tpx2 [targeting protein for Xklp2], INCENP [inner centromer protein]) with a known role in mitosis. Transfection of these siRNAs by liquid transfection of reverse transfection on LabTek dishes clearly caused mitotic phenotypes. We could clearly reproduce the already published prometaphase arrest phenotypes of EG5, 9 PLK1, 10 Tpx2. 11 After knockdown of INCENP, cells show multilobed nuclei due to segregation defects 12 ( Fig. 2A) . We calculated the phenotypic penetrance defined as the number of cells showing the phenotype of interest, divided by the total number of cells per image and compared the results with liquid-phase transfections in 96-well plates (Fig. 2B) . More than 50% of the cells show a clear mitotic arrest phenotype using solid-phase reverse transfection. For 2 (Eg5 and Tpx2) of the 4 genes we saw that solidphase transfection showed a higher penetrance. No genes were worse with solid-phase transfection, based on the error bars. Remarkably, we found that liquid-phase transfection is prone to result in dead cells (cells with fragmented nuclei), indicated by the red bars, whereas in the solid-phase reverse transfection experiments no dead cells are detected. This might be because in solid-phase transfection only a fraction of the cell surface is exposed to the transfection solution.
In Figure 3A we compared liquid-phase transfection versus solid-phase reverse transfection in 96-well plates on the basis of real-time quantitative RT-PCR (qRT-PCR). We measured the remaining mRNA levels of COPB (coat protein, subunit beta 1), INCENP, Eg5, Tpx2, and PLK1 in HeLa Kyoto cells and could not detect any significant difference between these 2 techniques.
Furthermore, we wanted to know if we reach a similar transfection efficiency in different cell lines coming from different tissues. Figure 3B cell types showing that we got very good transfection efficiencies with solid-phase reverse tranfection in these cell lines.
In addition, we could demonstrate that prefabricated replicas can be used without loss of transfection efficiency for at least 12 weeks after production (Fig. 4) . The mRNA depletion over storage time after production of the replicas showed no significant difference when comparing 1 week, 6 weeks, and 12 weeks of storage time. This proved the multiplex capacity of solid-phase reverse transfection in multiwell plates.
In summary, we could combine the advantages of solidphase reverse transfection and multiwell substrates resulting in a protocol giving access to high cell numbers and following up studies of cells, for example, RT-PCR. From our results we can conclude that solid-phase reverse transfection is a valid alternative to liquid-phase transfection in multiwell plates and will have utility in systems biology studies. Cyotoxicity is considerably reduced compared with liquid-phase transfection. This results in more assay-specific readouts. The dried and ready-to-transfect replicas can be stored for more than 12 weeks after production. One preparation round of solidphase plates serves, depending on the scale of production, for several different biological assays, which is not the case for liquid-phase transfection. This should result in a much higher level of comparability between the results of different assays because the plates for transfection are based on the same setup and source.
Further, due to the simultaneous preparation of several assays the costs of an experiment are considerably reduced. Liquid-phase transfection cannot be decoupled from cell seeding as in the case of solid-phase transfection. In solid-phase transfection the location and time of cell seeding can be separated, allowing laboratories even without expensive robotics to perform genome-wide RNAi screens. In addition cells can be seeded or infected at any given time point as soon as the cells or viruses are in an appropriate state. The possibility for decoupling the production of the replicas in time and space from the actual cell biological assay means that solid-phase reverse transfection is an ideal tool for multiplexing biological assays. The remaining mRNA levels of COPB (coat protein, subunit beta 1), INCENP, Eg5, Tpx2, and PLK1 showed no significant difference between these 2 techniques. (B) Here we addressed transfection efficiency of solid-phase reverse transfection in A549, U20S, and RPE cells, measured by real-time qRT-PCR in 96-well plates for the genes COPB, INCENP, and Eg5. We observed low levels of remaining mRNA in those usually hard-to-transfect cell types, meaning that we achieve a good transfection efficiency with solid-phase reverse tranfection in these cell lines. We could demonstrate that prefabricated solid-phase replicas can be used without obvious loss of transfection efficiency for at least 12 weeks after production. We compared the mRNA depletion after knockdown of the genes Eg5, PLK1, Tpx2, INCENP, and COPB over storage time after production of the replicas. The results showed no significant difference when comparing 1 week (red bars), 6 weeks (blue bars), and 12 weeks (green bars) of storage time.
